Genes involved in cell cycle G1 checkpoint control are frequently mutated in human melanoma metastases

British Journal of Cancer

Volumn 74, Issue 6, 1996, Pages 936-941

  Platz, A ^a   Sevigny, P ^b   Norberg, T ^b   Ring, P ^a   Lagerlof B ^a   Ringborg, U ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b GE Healthcare Bio Sciences AB   (Sweden)

Author keywords

CDKN2A; CDKN2B; Human melanoma metastases; N Ras mutation; Nucleotide sequence analysis; p53; Polymerase chain reaction single strand conformation polymorphism

Indexed keywords

ONCOPROTEIN; PROTEIN P53;

ARTICLE; CELL CYCLE G1 PHASE; CELL DIVISION; CLINICAL ARTICLE; CONTROLLED STUDY; GENE FREQUENCY; GENE MUTATION; HUMAN; HUMAN CELL; MELANOMA; METASTASIS; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM;

EID: 0029758420     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.460     Document Type: Article

References (44)

1. ALBINO AP, NANUS DM, MENTLEV IR, CORDON-CARDO C, MCNUTT NS, BRESSLER J AND ANDREFE M. (1989). Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype. Oncogene, 4, 1363-1374.
2. BALL NJ, YOHN JJ, MORELLI JG, NORRIS DA, GOLITZ LE AND HOEFFLER JP. (1994). Ras mutations in human melanoma: a marker of malignant progression. J. Invent. Dermatol., 102, 285-290.
3. BARBACID M. (1978). Ras genes. Annu. Rev. Biochem., 56, 779-827.
4. BOS JL. (1989). Ras oncogenes in human cancer: a review. Cancer Rex., 49, 4682-4689.
5. BUCHMAN VL, CHUMAKOV PM, NINKINA NN, SAMARINA OP AND GEORGIEV GP. (1988). A variation in the structure of the protein-coding region of the human p53 gene. Gene, 70, 245-252.
6. CALDAS C, HAHN SA, DA COSTA LT, REDSTON MS, SCHUTTE M, SKYMOUR AB, WEINSTEIN CL, HRUBAN RH, YEO CJ AND KERN SE. (1994). Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nature, Genet., 8, 27-32.
7. CANNON-ALBRIGHT LA, GOLDGAR ED, MEYER I.J, LEWIS CM, ANDERSON DE, FOUNTAIN JW, HEGI ME, WISEMAN RW, PETTY EM, BALE AE, OLOPADE OI, DIAZ MO, KWIATKOWSKI DJ, PIEPKORN MW, ZONE JJ AND SKOLNICK MH. (1992). Assignment of a locus for familial melanoma, MLM, to chromosome 9p13 p22. Science, 258, 1148-1152.
8. CASTRESANA JS, RUBIO MP, VASQUEZ JJ, IDOATE M, SOBER A, SEIZINGER BR AND BARNHILL RL. (1993). Lack of allelic deletion and point mutations as mechanisms of TP53 activation in human malignant melanoma. Int. J. Cancer, 55, 552-565.
9. CLURMAN BE AND ROBERTS JM. (1995). Cell cycle and cancer. J. Natl Cancer Inst., 87, 1499-1501.
10. CORDON-CARDO C. (1995). Mutation of cell cycle regulators: biological and clinical implications for human neoplasia. Am. J. Pathol., 147, 545-560.
11. EL-DIERY DW, TOKINO T, VELCULESCU VE, LEVY DB, PARSONS R, TRENT JM, LIN D, MERCER WE, KINZLER KW AND VOGELSTEIN B. (1993). WAF1, a potential mediator of p53 tumor suppression. Cell, 75, 817-825.
12. FILMUS J, ROBLES AI, SHI W, WONG MJ, COLOMBO LL AND CONTI CJ. (1994). Induction of cyclin D1 overexpression by activated ras. Oncogene, 9, 3627-3633.
13. FLORENES VA, OYJORD T, HOLM R, SKREDE M, BORRESEN AL, NESLAND JM AND FODSTAF O. (1994). Tp53 allele loss, mutations and expression in malignant melanoma. Int. J. Cancer, 69, 253-259.
14. GOLDSTEIN A, DRACOPOLI N, ENGELSTEIN M, FRASER MC, CLARK WH AND TUCKER MA. (1994). Linkage of cutaneous malignant melanoma dysplastic nevi (CMM/DN) to chromosome 9p and evidence for genetic heterogeneity. Am. J. Hum. Genet, 54, 489-496.
15. GRANA X AND REDDY P. (1995). Cell cycle control in mammalian cells, role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene, 11, 211-219.
16. GRUIS NA, WEAVER-FELDHAUS J, LIU Q, FRYE C, EELES R, ORLOW I, LACOMBE L, PONCE-CASTANEDA V, LIANES P, LATRES E, SKOLNICK M, CORDON-CARDO A AND KAMB A. (1995). Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression. Am. J. Pathol., 146, 1199-1206.
17. INK4B is a potential effector of TGF-beta induced cell cycle arrest. Nature, 371, 257-261.
18. HARRIS CC AND HOLLSTEIN M. (1992). p53 tumor suppressor gene. Principles Pract. Oncol., 6, 1-12.
19. HARTWELL LH AND KASTAN MB. (1994). Cell cycle control and cancer. Science, 266, 1821-1828.
20. HEDRUM A, PONTEN F, REN Z, LUNDEBERG J, PONTEN J AND UHLEN M. (1994). Sequence-based analysis of the human p53 gene based on microdissection of tumor biopsy samples. BioTechniques, 17, 118-129.
21. HOLLSTEIN M, SIDRANSKY Y, VOGELSTEIN B AND HARRIS CC. (1991). p53 mutations in human cancers. Science, 253, 49-53.
22. HUNTER T AND PINES J. (1994). Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell, 79, 573-582.
23. HUSSUSSIAN CJ, STRUEWING JP, GOLDSTEIN AM, HIGGINS PAT, ALLY DS, SHEAHAN MD, CLARK WH, TUCKER MA AND DRACOPOLI NC. (1994). Germline p16 mutations in familial melanoma. Nature Genet., 8, 15-21.
24. KAMB A, GRUIS NA, WEAVER-FELDHAUS J, LIU Q, HARSHMAN K, TAVTIGIAN SV, STOCKERT K, DAY III RS, JONSON BE AND SKOLNICK MH. (1994a). Cell cycle regulator potentially involved in genesis of many tumor types. Science, 264, 436-440.
25. KAMB A, SHATTUCK-EIDENS D, EELES R, LIU Q, GRUIS NA, DING W, HUSSEY C, TRAN T, MIKI Y, WEAVER-FELDHAUS J, MCCLURE M, AITKEN JH, ANDERSON DE, BERGMAN W, FRANTS R, GOLDGAR DK, GREEN A, MACLENNAN R, MARTIN NG, MEYER LJ, YOUL P, ZONE JJ, SKOLNICK MH AND CANNON-ALBRIGHT LA. (1994b). Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature Genet., 8, 22-26.
26. KISHIMOTO Y, MURAKAMI Y, SHIRAISHI M, HAYASHI K AND SEKIYA T. (1992). Abberations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung. Cancer Res., 52, 4799-4804.
27. LAGERKVIST A, STEWART J, LAGERSTRÖM-FERMER M AND LANDEGREN U. (1994). Manifold sequencing: efficient processing of large sets of sequencing reactions. Proc. Natl Acad. Sci. USA, 91, 2245-2249.
28. LEVINE AJ, MOMAND J AND FINLEY CA. (1991). The p53 tumor suppressor gene. Nature, 351, 453-456.
29. MASHIYAMA S, SEKIYA T AND HAYASHI K. (1990). Screening of multiple DNA samples for detection of sequence changes. Technique, 2, 304-306.
30. MORI T, MIURA K, ACKI T, HISHIHIRA T, MORI S AND NAKAMURA Y. (1994). Frequent somatic mutation of the MTS1/CDK41 (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res., 54, 3396-3397.
31. NAITO M, SATAKE M, SAKAI E, HIRANO Y, TSUCIDA N, KANZAKI H, ITO Y AND MORI T. (1992). Detection of p53 gene mutations in human ovarian and endometrial cancers by polymerase chain reaction-single strand conformation polymorphism analysis. Jpn J. Cancer Res., 83, 1030-1036.
32. NOBURI T, MURA K, WU DJ, LOIS A, TAKABAYASHI K AND CARSON DA. (1994). Detections of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature, 368, 753-756.
33. OHTA M, NAGAI H, SHIMIZU M, RASIO D, BERD D, MASTRANGELO M, SINGH AO, SHIELDS JA, SHIELDS CL, CROCE CL AND HUEBENER K. (1994). Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK41, in melanoma. Cancer Res., 54, 5269-5272.
34. INK4 in human cancer. Proc. Natl Acad. Sci. USA, 91, 11045-11049.
35. INK4b/MTS2) in pediatric acute lymphoblastic leukemia. Blood, 55, 1436-1440.
36. PLATZ A, RINGBORG U, MÅNSSON-BRAHME E AND LAGERLÖF B. (1994). Melanoma metastases from patients with hereditary cutaneous malignant melanoma contain a high frequency of N-ras activating mutations. Melanoma Res., 4, 169-177.
37. PLATZ A, HANSSON J, RINGBORG U, MÅNSSON-BRAHME E, LINDER S, LUNDQVIST E, SEVIGNY P AND INGANÄS M. (1995a). Germline p16 mutations are rare in Swedish melanoma families. In Proceedings of the 38th Annual Clinical Conference, MD Anderson Cancer Center, Feb 21 - 24, Houston, TX, pp. 84-85.
38. PLATZ A, RINGBORG U, GRAFSTRÖM E, HÖÖG A AND LAGERLÖF B. (1995b). Immunohistochemical analysis of the N-Ras p21 and the p53 proteins in naevi, primary tumours and metastases of human cutaneous malignant melanoma: increased immunopositivity in hereditary melanoma. Melanoma Res., 5, 101-106.
39. PLATZ A, RINGBORG U, LAGERLÖF B, LUNDQVIST E. SEVIGNY P AND INGANAS M. (1996). Mutational analysis of the CDKN2 gene in metastases from patients with cutaneous malignant melanoma. Br. J. Cancer, 73, 344-348.
40. SERRANO M, HANNON JH AND BEACH D. (1993). A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature, 366, 704-707.
41. SOUSSI T, LEGROS Y, LUBIN R, ORY K AND SCHLICHTHOLZ B. (1994). Multifactorial analysis of p53 alteration in human cancer: a review. Int. J. Cancer, 57, 1-9.
42. VAN'T VEER JL, BURGERING BMT, VEERSTEG R, BOOT AJM, RUITER DJ, OSANTO S, SCHRIER PJ AND BOS JL. (1989). N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Mol. Cell. Biol., 9, 3114-3116.
43. VOLKENANDT M, SCHLEGEL U, NANUS DM AND ALBINO AP. (1991). Mutational analysis of the human p53 in malignant melanoma. Pigment Cell Res., 4, 35-40.
44. ZHOU X, TARMIN L, YIN J, JIANG HY, SUZUKI H, RHYU MG, ABRAHAM JM AND MELTZER SJ. (1994). The MTS-1 gene is frequently mutated in primary human-esophageal tumors. Oncogene, 9, 3737-3741.